个人简历

周宇峰，男，1990年出生于浙江台州，农学博士，主要从事兽医药代动力学、药动/药效学同步模型、抗菌药敏感性折点及细菌耐药控制策略等研究，目前主持国家自然科学基金青年基金1项、广东省自然科学基金面上项目1项，以第一作者在《J Antimicrob Chemother》、《Antimicrob Agents Chemother》等国际期刊发表论文13篇，获2019年ChiCAST荣誉贡献个人奖。
教育经历
2017.08-2018.08，美国加州大学洛杉矶分校（UCLA），联合培养博士
2013.09-2018.12，华南农业大学，基础兽医学，博士（硕博连读）
2009.09-2013.06，华南农业大学，动物医学，学士
工作经历
2019.01-至今，华南农业大学，兽医学院，副教授
承担科研项目情况
1. 国家自然科学基金青年科学基金，2020.01-2022.12，主持
2. 广东省自然科学基金面上项目，2021.01-2023.12，主持
3. 华南农业大学人才引进科研启动项目，2019.01-2024.01，主持
4. 华南农业大学兽医学院扶基培优项目，2021.01-2022.12，主持
写给学生的话
好好学习，天天向上

研究领域

"兽医药代动力学、药动/药效学同步模型、抗菌药敏感性折点及耐药控制策略"

近期论文

1. Zhou YF, Liu P, Dai SH, Sun J, Liu YH, Liao XP. Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli Harboring tet(X) and mcr-1. Antimicrobial Agents and Chemotherapy 2021, 65:e01172-20.
2. Zhou YF, Liu P, Dai SH, Sun J, Liu YH, Liao XP. In Vivo Pharmacodynamic Target Assessment of Antofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a Neutropenic Murine Pneumonia Model. Antimicrobial Agents and Chemotherapy 2020, 64: e01354-20.
3. Zhou YF, Li L, Tao MT, Sun J, Liao XP, Liu YH, Xiong YQ. Linezolid and Rifampicin Combination to Combat cfr-Positive Multidrug-Resistant MRSA in Murine Models of Bacteremia and Skin and Skin Structure Infection. Frontiers in Microbiology 2020, 10:3080.
4. Zhou YF, Liu P, Zhang CJ, Liao XP, Sun J, Liu YH. Colistin Combined With Tigecycline: A Promising Alternative Strategy to Combat Escherichia coli Harboring bla NDM-5 and mcr-1. Frontiers in Microbiology 2020, 10:2957.
5. Zhou YF, Bu MX, Liu P, Sun J, Liu YH, Liao XP. Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets. BMC Veterinary Research 2020, 16:81.
6. Zhou YF, Xiong YQ, Tao MT, Li L, Bu MX, Sun J, Liao XP, Liu YH. Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA. Journal of Antimicrobial Chemotherapy, 2018, 73 (7):1899-1907.
7. Zhou YF, Tao MT, He YZ, Sun J, Liu YH, Liao XP. In vivo bioluminescent monitoring of therapeutic efficacy and pharmacodynamic target assessment of antofloxacin against Escherichia coli in a neutropenic murine thigh infection model. Antimicrobial Agents and Chemotherapy, 2018, 62 (1):e01281-17.
8. Zhou YF, Tao MT, Feng Y, Yang RS, Liao XP, Liu YH, Sun J. Increased activity of colistin in combination with amikacin against Escherichia coli co-producing NDM-5 and MCR-1. Journal of Antimicrobial Chemotherapy, 2017, 72 (6):1723-1730.
9. Zhou YF, Tao MT, Huo W, Liao XP, Sun J, Liu YH. In vivo pharmacokinetic and pharmacodynamic profiles of antofloxacin against Klebsiella pneumoniae in a neutropenic murine lung infection model. Antimicrobial Agents and Chemotherapy, 2017, 61 (5): e02691-16.
10. Zhou YF, Peng HM, Bu MX, Liu YH, Sun J, Liao XP. Pharmacodynamic evaluation and PK/PD-based dose prediction of tulathromycin: a potential new indication for Streptococcus suis infection. Frontiers in Pharmacology, 2017, 8:684.
11. Zhou YF, Shi W, Yu Y, Tao MT, Xiong YQ, Sun J, Liu YH. Pharmacokinetic/ pharmacodynamic correlation of cefquinome against experimental catheter-associated biofilm infection due to Staphylococcus aureus. Frontiers in Microbiology, 2016, 6:1513.
12. Zhou YF, Yu Y, Sun J, Tao MT, Zhou WJ, Li X, Liao XP, Liu YH. Ex vivo pharmacokinetic/pharmacodynamic relationship of valnemulin against Clostridium perfringens in plasma, the small intestinal and caecal contents of rabbits. Anaerobe, 2016, 39:150-157.
13. Zhou YF, Zhao DH, Yu Y, Yang X, Shi W, Peng YB, Liu YH. Pharmacokinetics, bioavailability and PK/PD relationship of cefquinome for Escherichia coli in Beagle dogs. Journal of Veterinary Pharmacology and Therapeutics, 2015, 38 (6):543-548.